Spiriva and Dermatitis atopic aggravated - a phase IV clinical study of FDA data

Summary:

Dermatitis atopic aggravated is reported as a side effect among people who take Spiriva (tiotropium bromide monohydrate), especially for people who are female, 60+ old, also take Dupixent, and have Eczema.

The phase IV clinical study analyzes which people have Dermatitis atopic aggravated when taking Spiriva. It is created by eHealthMe based on reports of 155,418 people who have side effects when taking Spiriva from the FDA, and is updated regularly.

What is Spiriva?

Spiriva has active ingredients of tiotropium bromide monohydrate. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 156,666 Spiriva users. Check the latest studies of Spiriva.

What is Dermatitis atopic aggravated?

Dermatitis atopic aggravated (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder) is found to be associated with 612 drugs and 179 conditions by eHealthMe. Check the latest studies of Dermatitis atopic aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

155,418 people reported to have side effects when taking Spiriva.
Among them, 72 people (0.05%) have Dermatitis atopic aggravated.

Could Spiriva cause Dermatitis atopic aggravated?

Among these 72 people:

What is the gender of people who have Dermatitis atopic aggravated when taking Spiriva? *

female: 60.66 %
male: 39.34 %

What is the age of people who have Dermatitis atopic aggravated when taking Spiriva? *

What are other drugs people take besides Spiriva? *

What are other side effects people have besides Dermatitis atopic aggravated? *

What are the existing conditions these people have? *

Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 5 people, 6.94%
Mycosis Fungoides (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin): 2 people, 2.78%
Dermatitis Allergic (inflammation of the skin due allergic reaction): 2 people, 2.78%
Urticaria (rash of round, red welts on the skin that itch intensely): 1 person, 1.39%
Idiopathic Thrombocytopenic Purpura (Itp) (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 1 person, 1.39%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 1.39%
Cough: 1 person, 1.39%
Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 1.39%

* Approximation only. Some reports may have incomplete information.

Do you take Spiriva and have Dermatitis atopic aggravated?

- Check whether Dermatitis atopic aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Spiriva:

Spiriva (156,666 reports)

Dermatitis atopic aggravated treatments and more:

Dermatitis atopic aggravated (31 reports)

How severe was Dermatitis atopic aggravated and when was it recovered:

Dermatitis atopic aggravated in Spiriva

Expand to all the drugs that have ingredients of tiotropium bromide monohydrate:

Dermatitis atopic aggravated and drugs with ingredients of tiotropium bromide monohydrate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Spiriva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis atopic aggravated:

Dermatitis atopic aggravated (612 drugs)

Browse all the conditions that are associated with Dermatitis atopic aggravated:

Dermatitis atopic aggravated (179 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tiotropium bromide monohydrate (the active ingredients of Spiriva) and Spiriva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.